As filed with the Securities and Exchange Commission on November 9, 2012

Registration No.        

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

FORM S-8

 

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

OSIRIS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Maryland

 

71-0881115

(State or other jurisdiction of

 

(I.R.S. Employer Identification No.)

incorporation or organization)

 

 

 

7015 Albert Einstein Drive

 

 

Columbia, Maryland

 

21046

(Address of Principal Executive Offices)

 

(Zip Code)

 

Osiris Therapeutics, Inc.

Amended and Restated 2006 Omnibus Plan
(formerly referred to as the “Osiris Therapeutics, Inc.

Amended and Restated 2006 Omnibus Plan, as

amended and restated effective May 27, 2010”)

(Full title of the plan)

 

C. Randal Mills, Ph.D.

President and Chief Executive Officer

Osiris Therapeutics, Inc.

7015 Albert Einstein Drive

Columbia, MD  21046

(Name and address of agent for service)

 

(443) 545-1819

(Telephone number, including area code, of agent for service)

 

with a copy to:

 

Douglas M. Fox, Esquire

Ballard Spahr LLP

18th Floor

300 East Lombard Street

Baltimore, MD 21202-3268

(410) 528-5600

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b- 2 of the Exchange Act.

 

Large accelerated filer o

 

Accelerated filer x

Non-accelerated filer o (Do not check if a smaller reporting company)

 

Smaller reporting company o

 

CALCULATION OF REGISTRATION FEE

 

Title of Securities to
be Registered

 

Amount to be
Registered(1)

 

Proposed Maximum
Offering Price Per
Share(2)

 

Proposed Maximum
Aggregate Offering
Price(2)

 

Amount of
Registration Fee(3)

 

Common Stock, par value $0.001 per share

 

300,000 shares

 

$

10.37

 

$

3,111,000

 

$

424.34

 

(1)                                  Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall be deemed to cover an indeterminate number of additional shares of Common Stock issuable in the event the number of outstanding shares of the Registrant is increased by reason of any stock dividend, stock split, recapitalization, merger, consolidation or reorganization or similar transaction.

 

(2)                                  Estimated solely for the purpose of calculating the registration fee.  In accordance with Rule 457(h) promulgated under the Securities Act, the price shown is based upon the average of the high and low prices reported for the Common Stock on the NASDAQ Global Market on November 6, 2012.

 

(3)                                  Calculated under Section 6(b) of the Securities Act as .0001364 of the aggregate offering price.

 

 

 



 

PART II -

 

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

 

Explanatory Note

 

Osiris Therapeutics, Inc. (the “Registrant”) is filing this registration statement to register an additional 300,000 shares of the Registrant’s common stock, par value $0.001 per share (the “Common Stock”), for issuance under the Osiris Therapeutics, Inc. Amended and Restated 2006 Omnibus Plan (as previously existing or as amended, or amended and restated, from time to time, as the context so dictates, the “Plan”).  The increase in the number of shares authorized for issuance under the Plan, as well as certain other amendments to the Plan that are described in the Registrant’s definitive proxy statement, filed with the United States Securities and Exchange Commission (the “Commission”) on April 27, 2012, were approved by the Registrant’s stockholders on June 11, 2012.

 

The Registrant previously filed a registration statement on Form S-8 (Reg. No. 333-137952), a Post-Effective Amendment No. 1 to Registration Statement on Form S-8 (Reg. No. 333-137952) and a registration statement on Form S-8 (Reg. No. 333-167652) covering an aggregate of 1,950,000 shares of Common Stock authorized for issuance under the Plan.  Upon the effectiveness of this Registration Statement, an aggregate of 2,250,000 shares of Common Stock will have been registered for issuance from time to time under the Plan.  Pursuant to General Instruction E to Form S-8, the contents of the earlier registration statements (including the post-effective amendment) are incorporated herein by reference except to the extent supplemented, amended or superseded by the information set forth herein.  Only those items of Form S-8 containing new information not contained in the earlier registration statements are presented herein.

 

Item 3.                                                          Incorporation of Documents by Reference.

 

The following documents, which have previously been filed with the Commission by the Registrant, are hereby incorporated by reference into this Registration Statement and made a part hereof:

 

·                                           Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011, filed with the Commission on March 14, 2012;

 

·                                           Registrant’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2012, filed with the Commission on May 10, 2012, the Registrant’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2012, filed with the Commission on August 9, 2012, and the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2012, filed with the Commission on November 9, 2012;

 

·                                           all other reports of the Registrant filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of Registrant’s most recent fiscal year ended December 31, 2011 (except for any reports, or portions of reports, that are not deemed “filed” with the Commission); and

 

·                                           the description of the Common Stock contained in the Registration Statement on Form 8-A/A, filed with the Commission on June 18, 2010, pursuant to Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description.

 

In addition, all reports and other documents subsequently filed by the Registrant after the date hereof pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and shall be part hereof from the date of filing of such document.  Any statement contained in a document, all or a portion of which is incorporated by reference herein, shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained or incorporated by reference herein modifies or supersedes such statement.  Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.  The Registrant is not, however, incorporating by reference any documents, or portions of

 

2



 

documents, that are not deemed “filed” with the Commission.

 

Item 8.                    Exhibits.

 

Exhibit

 

 

Number

 

Description

 

 

 

4.1

 

Articles of Restatement of the Registrant as filed with the State Department of Assessments and Taxation of Maryland on June 4, 2010 (Incorporated herein by reference to Exhibit 3.1 to the Quarterly Report on Form 10-Q filed by the Registrant with the Commission on August 6, 2010)

 

 

 

4.2

 

Bylaws of the Registrant. (Incorporated herein by reference to Exhibit 3.3 to the Registrant’s Current Report on Form 8-K, filed with the Commission on June 2, 2010)

 

 

 

4.3

 

Osiris Therapeutics, Inc. Amended and Restated 2006 Omnibus Plan (as amended and restated effective May 27, 2010). (Incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed with the Commission on June 2, 2010)

 

 

 

4.4

 

First Amendment to Osiris Therapeutics, Inc. Amended and Restated 2006 Omnibus Plan. (filed herewith)

 

 

 

5.1

 

Opinion of Ballard Spahr LLP. (filed herewith)

 

 

 

23.1

 

Consent of Grant Thornton LLP. (filed herewith)

 

 

 

23.2

 

Consent of Ballard Spahr LLP. (included in Exhibit 5.1)

 

 

 

24.1

 

Power of Attorney. (filed herewith)

 

3



 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the County of Howard, State of Maryland, on November 9, 2012.

 

 

Osiris Therapeutics, Inc.

 

 

 

 

 

By:

/s/ C. Randal Mills

 

Name:

C. Randal Mills, Ph.D.

 

Title:

President and Chief Executive Officer

 

 

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signature

 

Title

 

Date

 

 

 

 

 

 

 

 

 

 

/s/ C. Randal Mills

 

President, Chief Executive Officer and Director

 

November 9, 2012

C. Randal Mills, Ph.D.

 

(Principal Executive Officer)

 

 

 

 

 

 

 

 

 

 

 

 

/s/ Philip R. Jacoby, Jr.

 

Chief Financial Officer and Corporate Secretary

 

November 9, 2012

Philip R. Jacoby, Jr.

 

(Principal Financial Officer)

 

 

 

 

 

 

 

 

 

 

 

 

/s/ Matthew Neumayer

 

Corporate Controller

 

November 9, 2012

Matthew Neumayer

 

(Principal Accounting Officer)

 

 

 

 

 

 

 

 

 

 

 

 

*

 

Director

 

November 9, 2012

Peter Friedli

 

 

 

 

 

 

 

 

 

 

 

 

 

 

*

 

Director

 

November 9, 2012

Felix Gutzwiller

 

 

 

 

 

 

 

 

 

 

 

 

 

 

*

 

Director

 

November 9, 2012

Jay M. Moyes

 

 

 

 

 

 

 

 

 

 

 

 

 

 

*

 

Director

 

November 9, 2012

Hans-Georg Klingemann

 

 

 

 

 

*By:

/s/ Philip R. Jacoby, Jr.

 

 

 

 

 

Philip R. Jacoby, Jr.

 

 

 

 

 

Attorney-in-Fact

 

 

 

 

 

4



 

EXHIBIT INDEX

 

Exhibit

 

 

Number

 

Description

 

 

 

4.1

 

Articles of Restatement of the Registrant as filed with the State Department of Assessments and Taxation of Maryland on June 4, 2010 (Incorporated herein by reference to Exhibit 3.1 to the Quarterly Report on Form 10-Q filed by the Registrant with the Commission on August 6, 2010)

 

 

 

4.2

 

Bylaws of the Registrant. (Incorporated herein by reference to Exhibit 3.3 to the Registrant’s Current Report on Form 8-K, filed with the Commission on June 2, 2010)

 

 

 

4.3

 

Osiris Therapeutics, Inc. Amended and Restated 2006 Omnibus Plan (as amended and restated effective May 27, 2010). (Incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed with the Commission on June 2, 2010)

 

 

 

4.4

 

First Amendment to Osiris Therapeutics, Inc. Amended and Restated 2006 Omnibus Plan. (filed herewith)

 

 

 

5.1

 

Opinion of Ballard Spahr LLP. (filed herewith)

 

 

 

23.1

 

Consent of Grant Thornton LLP. (filed herewith)

 

 

 

23.2

 

Consent of Ballard Spahr LLP. (included in Exhibit 5.1)

 

 

 

24.1

 

Power of Attorney. (filed herewith)

 

5


Exhibit 4.4

 

First Amendment to Osiris Therapeutics, Inc.

Amended and Restated 2006 Omnibus Plan

 

This FIRST AMENDMENT TO OSIRIS THERAPEUTICS, INC. AMENDED AND RESTATED 2006 OMNIBUS PLAN, of Osiris Therapeutics, Inc., a Maryland corporation (the “Company”), memorializes the amendment to the Osiris Therapeutics, Inc. Amended and Restated 2006 Omnibus Plan (as previously existing or as amended, or amended and restated, from time to time, as the context dictates, the “Plan”), as hereinafter set forth.  Capitalized terms used herein and not otherwise defined shall have the meaning ascribed thereto in the Plan.

 

1.             The aggregate number of shares of Common Stock that may be issued at any time pursuant to awards granted under the Plan has been increased by 300,000, from 1,950,000 to 2,250,000, subject to further adjustment from time to time provided under the terms of the Plan, and to that end, the first sentence of Section 3.3 of the Plan is amended to read in full as follows:

 

“Subject to the provisions of Section 4.1(e) (relating to adjustment for changes in Common Stock), the maximum number of shares that may be issued under this Plan shall not exceed in the aggregate 2,250,000 shares of Common Stock.”

 

2.             The termination date of the Plan has been extended from May 27, 2020 to June 11, 2022, and to that end, the last sentence of Section 10.2 of the Plan is amended to read in full as follows:

 

“Unless sooner terminated by the Committee, this Plan will terminate on June 11, 2022; it being acknowledged, however, for the avoidance of doubt, that any awards granted or made prior to any termination will not be affected thereby.”

 

The foregoing amendments to the Plan were approved by the Board of Directors of the Company and the stockholders of the Company in accordance with applicable law, effective as of June 11, 2012, and reflect the resolutions of the stockholders approved at the Annual Meeting of Stockholders of the Company held on June 11, 2012 (the “2012 Annual Meeting”), in the form of such resolutions attached as Appendix A to the Proxy Statement on Schedule 14-A for the 2012 Annual Meeting, as filed with the United States Securities and Exchange Commission on April 27, 2012.  By order of the Board of Directors of the Company, this First Amendment to Osiris Therapeutics, Inc. Amended and Restated 2006 Omnibus Plan, memorializing the amendments to the Plan as aforesaid, shall be appended to and become part of the Plan.

 


Exhibit 5.1

 

[LETTERHEAD OF BALLARD SPAHR LLP]

 

 

November 9, 2012

 

Osiris Therapeutics, Inc.

7015 Albert Einstein Drive

Columbia, Maryland  21046

 

Re:                              Osiris Therapeutics, Inc., a Maryland corporation (the “Corporation”) — Registration Statement on Form S-8 to be filed on or about the date hereof relating to 300,000 additional shares (the “Shares”) of common stock, par value $.001 per share (“Common Stock”), of the Corporation subject to sale under the Osiris Therapeutics, Inc. Amended and Restated 2006 Omnibus Plan (as previously existing or as amended, or amended and restated, from time to time, as the context so dictates, the “Plan”)

 

Ladies and Gentlemen:

 

In connection with the registration by the Corporation of the Shares under a Registration Statement on Form S-8 (the “Registration Statement”), filed on or about the date hereof with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “1933 Act”), you have requested our opinion as to the matters set forth below.

 

We have acted as counsel to the Corporation in connection with the matters described herein. In our capacity as counsel to the Corporation, we have reviewed and relied upon one or more certificates from the officers of the Corporation and on various certificates from, and documents filed with, the Maryland State Department of Assessments and Taxation (the “Department”), including the charter of the Corporation, evidenced by Articles of Restatement filed with the Department on June 4, 2010.  We have also reviewed and are familiar with (a) the bylaws of the Corporation, (b) certain resolutions adopted or actions taken by the Board of Directors and stockholders of the Corporation, and in full force and effect on the date hereof, relating to the authorization and approval of the Plan and the authorization of the issuance and registration of the Shares (the “Resolutions”), (c) the Plan, (d) the Registration Statement and (e) such laws, records, documents, certificates, opinions and instruments as we deem necessary to render this opinion.

 

In rendering the opinion set forth below, we have assumed the genuineness of all signatures and the authenticity of all documents submitted to us as originals and the conformity to the originals of all documents submitted to us as certified, photostatic or conformed copies.  In addition, we have assumed that each person executing any instrument, document or certificate referred to herein on behalf of any party is duly authorized to do so.  We have further assumed that the number of Shares issued by the Corporation from the authorized but unissued shares of Common Stock of the Corporation pursuant to the Plan will not exceed 300,000 and that upon the issuance of any of the Shares subsequent to the date hereof, the total number of shares of Common Stock of the Corporation issued and outstanding on the date subsequent to the date hereof on which such Shares are issued will not exceed the total number of shares of Common Stock that the Corporation is authorized to issue under its charter.

 

Based upon the foregoing and subject to the assumptions, limitations and qualifications set forth herein, it is our opinion that, as of the date of this letter:

 

The Shares have been duly authorized for issuance and, when issued and delivered upon receipt of the consideration therefor as contemplated by the Plan and otherwise in accordance with the Resolutions, will be legally issued, fully paid and nonassessable.

 



 

The foregoing opinion is limited to the substantive laws of the State of Maryland and we do not express any opinion herein concerning any other law.  We express no opinion as to the applicability or effect of any federal or state securities laws, including the securities laws of the State of Maryland.  To the extent that any matter as to which our opinion is expressed herein would be governed by the laws of any jurisdiction other than the State of Maryland, we do not express any opinion on such matter.

 

We assume no obligation to supplement this opinion if any applicable law changes after the date hereof or if we become aware of any fact that might change the opinion expressed herein after the date hereof.

 

This opinion is being furnished to you solely for submission to the Commission as an exhibit to the Registration Statement.  We consent to the filing of this opinion as an exhibit to the Registration Statement.  In giving this consent, we do not admit that we are within the category of persons whose consent is required by Section 7 of the 1933 Act.

 

 

Very truly yours,

 

 

 

/s/ BALLARD SPAHR LLP

 

2


Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We have issued our reports dated March 14, 2012 with respect to the financial statements, schedule and internal control over financial reporting included in the Annual Report on Form 10-K for the year ended December 31, 2011 of Osiris Therapeutics, Inc., which are incorporated by reference in this Registration Statement. We consent to the incorporation by reference in the Registration Statement of the aforementioned reports.

 

 

/s/ GRANT THORNTON LLP

 

 

Baltimore, Maryland

November 9, 2012

 


Exhibit 24.1

 

POWER OF ATTORNEY

 

THE UNDERSIGNED directors of Osiris Therapeutics, Inc. do hereby appoint C. Randal Mills and Philip R. Jacoby, Jr., and each of them, to be their attorneys in fact and agents with full power of substitution and re-substitution, for each of such directors, with full power and authority and in their name, place and stead, in any and all capacities, to sign any Registration Statement, any pre or post- effective amendment(s) or supplements to any Registration Statement, and to do any and all things and to file the same with the Commission, and to perform all other acts and deeds on their behalf and in their name, and to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or they might or could do in person, in connection with any matter relating to any now existing or future Registration Statement on Form S-8 or otherwise, and to register, or cause to be registered with the Commission any and all shares of common stock issuable from time to time under the Osiris Therapeutics Inc. Amended and Restated 1994 Stock Incentive Plan, as amended, and the Osiris Therapeutics, Inc. Amended and Restated 2006 Omnibus Plan, as amended or amended and restated from time to time, and further hereby confirming all that said attorneys in fact and agents or any of them or their substitute or substitutes may lawfully do or cause to be done by virtue thereof.

 

 

/s/ Peter Friedli

 

Director

September 18, 2012

Peter Friedli

 

 

 

 

 

 

 

 

 

 

 

/s/ Felix Gutzwiller

 

Director

September 18, 2012

Felix Gutzwiller

 

 

 

 

 

 

 

 

 

 

 

/s/ Jay M. Moyes

 

Director

September 18, 2012

Jay M. Moyes

 

 

 

 

 

 

 

 

 

 

 

/s/ Hans-Georg Klingemann

 

Director

November 7, 2012

Hans-Georg Klingemann